All In Biotech

Drug Trial Radar · NCT06473948

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

27

Planned (sponsor's estimate)

Start

Jul 10, 2024

Primary completion

Sep 24, 2024

Study completion Feb 27, 2025

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers

Conditions

  • Solid Tumor, Adult

Interventions

  • JMKX001899Drug

    Participants will receive JMKX001899 500mg tablet, orally once on Day 1

  • JMKX001899Drug

    Participants will receive JMKX001899 750mg tablet, orally once on Day 1

  • JMKX001899Drug

    Participants will receive JMKX001899 1000mg tablet, orally once on Day 1

  • PlaceboDrug

    Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of a single dose of JMKX001899 on the change in time-matched QTc intervals compared with placeboTime frame: 48 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.